AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.24-2.44 (-1.23%) ▼|SBUX98.44-0.30 (-0.30%) ▼|SCHW107.43+0.18 (+0.17%) ▲|SO86.82-0.35 (-0.40%) ▼|SPG206.10+1.27 (+0.62%) ▲|T26.28+0.22 (+0.84%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN263.67-5.03 (-1.87%) ▼|UBER72.27+0.60 (+0.84%) ▲|UNH384.35+7.58 (+2.01%) ▲|UNP283.89-0.52 (-0.18%) ▼|UPS101.70+1.42 (+1.42%) ▲|USB62.82-0.02 (-0.03%) ▼|V376.00+5.55 (+1.50%) ▲|VZ51.13+0.52 (+1.02%) ▲|WFC88.54-1.75 (-1.94%) ▼|WMT109.06+1.91 (+1.78%) ▲|XOM165.91-0.09 (-0.05%) ▼|AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.24-2.44 (-1.23%) ▼|SBUX98.44-0.30 (-0.30%) ▼|SCHW107.43+0.18 (+0.17%) ▲|SO86.82-0.35 (-0.40%) ▼|SPG206.10+1.27 (+0.62%) ▲|T26.28+0.22 (+0.84%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN263.67-5.03 (-1.87%) ▼|UBER72.27+0.60 (+0.84%) ▲|UNH384.35+7.58 (+2.01%) ▲|UNP283.89-0.52 (-0.18%) ▼|UPS101.70+1.42 (+1.42%) ▲|USB62.82-0.02 (-0.03%) ▼|V376.00+5.55 (+1.50%) ▲|VZ51.13+0.52 (+1.02%) ▲|WFC88.54-1.75 (-1.94%) ▼|WMT109.06+1.91 (+1.78%) ▲|XOM165.91-0.09 (-0.05%) ▼|
22.2 C
New York
Monday, September 14, 2026

Tag: 14

Direxion to Split Nine ETFs

Direxion to Split Nine ETFs

Canada takes action to advance a stronger grid and increase reliable, affordable energy

YELLOWKNIFE, NT, June 26, 2026 /CNW/ - The world is changing rapidly: global trade has been upended, artificial intelligence is scaling at speed, and...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

FIA Divulga Conjunto de Resultados Financeiros Mais Sólidos dos Últimos 10 Anos

PARIS, June 26, 2026 (GLOBE NEWSWIRE) -- A Fédération Internationale de l'Automobile (FIA), órgão regulador global do automobilismo e federação de organizações de mobilidade em todo o mundo, divulgou hoje seu resultado operacional mais sólido dos últimos 10 anos.

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

Milei opens up to Ismael Cala: Childhood traumas, the Torah, and the fall of Cuba

EXCLUSIVE INTERVIEWIn a historic and extensive interview lasting over an hour with journalist Ismael Cala, the President of the Argentine Republic strips away his...

Milei opens up to Ismael Cala: Childhood traumas, the Torah, and the fall of Cuba

EXCLUSIVE INTERVIEWIn a historic and extensive interview lasting over an hour with journalist Ismael Cala, the President of the Argentine Republic strips away his...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Disclosure of transparency notification (article 14, first paragraph, of the Law of 2 May 2007)

Vastned NV has received on 24 June 2026 a transparency notification dated 23 June 2026, which indicates that Lebaras Invest B.V., as a result of the acquisition of shares on 19 June 2026, now holds more than 10% of the voting rights of Vastned NV. Lebaras Invest B.V. has thus crossed the 10% threshold (upward).

Openbaarmaking van transparantiekennisgeving (artikel 14, eerste lid van de Wet van 2 mei 2007)

Vastned NV heeft op 24 juni 2026 een transparantiekennisgeving, gedateerd op 23 juni 2026, ontvangen waaruit blijkt dat Lebaras Invest B.V., ingevolge de verwerving van aandelen op 19 juni 2026, nu meer dan 10% van de stemrechten van Vastned NV bezit. Lebaras Invest B.V. heeft daarmee de deelnemingsdrempel van 10% overschreden.  

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses
If finalized, rule would level the playing field between American and foreign businesses

La FIA presenta sus mejores resultados financieros de la última década

PARIS, June 26, 2026 (GLOBE NEWSWIRE) -- La Federación Internacional del Automóvil (FIA), organismo rector del automovilismo deportivo a nivel mundial y Federación de Entidades de Movilidad en todo el mundo, ha presentado hoy sus mejores resultados económicos en 10 años.

FIA Delivers Strongest Set of Financial Results in a Decade

FIA posts best financial results in a decade: €6.7M operating profit in 2025, revenues of €191.7M, and cash doubled to €43.6M

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags14